- Rimegepant 75 mg, already approved for the acute treatment of migraine, demonstrated efficacy and safety for the preventive treatment of migraine in this pivotal Phase 3 trial in adults
- Rimegepant resulted in a -4.3 day reduction in the mean number of migraine days per month
- Approximately half of rimegepant-treated patients demonstrated a 50% or greater reduction in the number of moderate-to-severe migraine days per month
- Rimegepant is the first and only CGRP targeting medication in development to show dual efficacy for both the acute and preventive treatment of migraine
PR Newswire
NEW HAVEN, Conn., Dec. 16, 2020
